Albireo Pharma Inc. (ALBO)’s Financial Results Comparing With Intrexon Corporation (NASDAQ:XON)

This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Albireo Pharma Inc. (NASDAQ:ALBO) and Intrexon Corporation (NASDAQ:XON). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Albireo Pharma Inc. 30 161.69 N/A -3.87 0.00
Intrexon Corporation 6 9.37 N/A -3.89 0.00

Table 1 highlights Albireo Pharma Inc. and Intrexon Corporation’s top-line revenue, earnings per share and valuation.


Table 2 provides us Albireo Pharma Inc. and Intrexon Corporation’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Albireo Pharma Inc. 0.00% -47% -32.3%
Intrexon Corporation 0.00% 0% 0%

Volatility & Risk

Albireo Pharma Inc.’s current beta is 1.73 and it happens to be 73.00% more volatile than S&P 500. Competitively, Intrexon Corporation is 112.00% more volatile than S&P 500, because of the 2.12 beta.


The Current Ratio and Quick Ratio of Albireo Pharma Inc. are 15.5 and 15.5 respectively. Its competitor Intrexon Corporation’s Current Ratio is 3.9 and its Quick Ratio is 3.6. Albireo Pharma Inc. can pay off short and long-term obligations better than Intrexon Corporation.

Analyst Ratings

Albireo Pharma Inc. and Intrexon Corporation Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Albireo Pharma Inc. 0 0 1 3.00
Intrexon Corporation 0 0 0 0.00

$62 is Albireo Pharma Inc.’s consensus price target while its potential upside is 119.00%.

Insider and Institutional Ownership

Institutional investors held 75.7% of Albireo Pharma Inc. shares and 75.4% of Intrexon Corporation shares. Insiders held roughly 0.4% of Albireo Pharma Inc.’s shares. Insiders Comparatively, held 0.6% of Intrexon Corporation shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Albireo Pharma Inc. 4.41% 18.46% 45.62% 46.52% 22.72% 54.34%
Intrexon Corporation 7.01% -0.63% -38.49% -56.08% -69.39% -27.68%

For the past year Albireo Pharma Inc. had bullish trend while Intrexon Corporation had bearish trend.


On 6 of the 8 factors Albireo Pharma Inc. beats Intrexon Corporation.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.